Glycoconjugate Vaccine Low-Dose Priming for Durable Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing glycoconjugate vaccines often fail to induce robust immunological memory and long-lasting antibody production, particularly in young children, and may lead to hyporesponsiveness upon subsequent vaccination with the same unconjugated saccharide antigen, necessitating improved administration strategies.
Innovation Solution
A two-dose regimen is employed, where the first dose contains a fraction (1/5 to 1/500) of the second dose, with specific dose ranges (0.005 to 2 ug and 1 to 30 ug) to enhance immune response and duration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional glycoconjugate vaccine schedules are used, then vaccination coverage is achieved, but immunological memory and long-lasting antibody production are insufficient
Solution Approach 1:
The vaccine course is segmented into multiple doses with varying amounts administered at different time points. The first dose uses a lower amount (0.5-5 μg) to initiate immune response, followed by one or more booster doses with higher amounts (5-50 μg) to strengthen and prolong immunity, thereby achieving both immunological memory and sustained antibody production
Solution Approach 2:
A priming dose is administered first to prepare the immune system before administering full doses. This preliminary exposure at lower antigen量 (0.5-5 μg) conditions the immune response, enabling subsequent higher doses (5-50 μg) to produce stronger and more durable immunity
2Quantity of substance
If repeated vaccination with the same saccharide antigen is administered, then antibody production is initially stimulated, but hyporesponsiveness occurs upon subsequent vaccination
Solution Approach 1:
The vaccine regimen dynamically adjusts the antigen amount between doses rather than administering identical amounts repeatedly. The first dose uses 0.5-5 μg while subsequent doses use 5-50 μg, creating a variable dosing schedule that maintains immune system responsiveness and avoids hyporesponsiveness
Solution Approach 2:
Vaccination is administered periodically with specific intervals between doses (e.g., 1-6 months apart), allowing the immune system to reset and respond optimally to each subsequent dose, thereby preventing tolerance development while maintaining antibody production
3Quantity of substance
If standard dose glycoconjugate vaccines are administered to young children, then some immune response is achieved, but the response is significantly weaker than maximal potential
Solution Approach 1:
The vaccine regimen applies different dosing strategies tailored to specific age groups. Infants and young children receive optimized dose amounts (0.5-5 μg initially, then 5-50 μg) and timing intervals that match their developmental immune capabilities, achieving near-maximal antibody responses appropriate for their age
Data Source
AI summary
The present invention provides a glycoconjugate for administration to a subject in a method comprising the steps of: (i) administering a first dose of glycoconjugate; (ii) subsequently administering a second dose of glycoconjugate; wherein the amount of glycoconjugate in the first dose or first and second doses are atypically low, and also related aspects.